论文部分内容阅读
硝普钠(NTP)被用于治疗冠状动脉介入治疗后的冠状动脉慢血流(SCF)。在以往报道中剂量、给药途径以及给药时间差异较大,妨碍了对其效果的客观评价。本文报道了在成功置入支架后SCF的发生率,以及予标准NTP方案治疗后的变化。2005年1月至10月间成功置入支架的2212例连续患者中有21例出现SCF,对这21例患者选择性冠状动脉内给予递增剂量NTP(首剂80μg,随后以40μg递增)并进行评估。SCF仅见于急性心肌梗死(AMI;11.5%,105例中的12例)或大隐静脉桥血管(SVG)狭窄(8.2%,109例中出现9例)的患者中。
Sodium nitroprusside (NTP) is used to treat coronary arterial slow-flow (SCF) after coronary intervention. In the past reported in the dose, route of administration and administration time is quite different, hindering the objective evaluation of its effect. This article reports the incidence of SCF after successful stent placement and changes after treatment with standard NTP regimens. SCF was observed in 21 of 2212 consecutive patients who were successfully placed in stents between January and October 2005 and were given selective intracoronary administration of increasing doses of NTP (first dose 80 μg followed by 40 μg) followed by Evaluation. SCF was found only in patients with acute myocardial infarction (AMI; 11.5%; 12 of 105) or stenosed saphenous vein grafts (8.2%, 9 of 109).